Alinity m HBV

FDA Premarket Approval P200013

Pre-market Approval Supplement Details

Approval for the alinity m hbv test. This device is indicated for:the alinity m hbv assay is an in vitro polymerase chain reaction (pcr) with fluorescent labeled probes assay for use with the automated alinity m system to quantitate hepatitis b virus (hbv) dna in human plasma and serum. The alinity m hbv assay is intended for use as an aid in the management of patients with chronic hbv infection undergoing anti-viral therapy. The assay can be used to measure hbv dna levels at baseline and during treatment to aid in assessing response to treatment. The results from the alinity m hbv assay must be interpreted within the context of all relevant clinical and laboratory findings. This assay is not intended to be used in screening blood, blood products, or cell, tissue, and cellular and tissue-based products (hct/ps), or as a diagnostic test to confirm the presence of hbv infection.

DeviceAlinity m HBV
Generic NameHepatitis Viral B Dna Detection
ApplicantAbbott Molecular, Inc.
Date Received2020-03-02
Decision Date2020-08-29
PMAP200013
SupplementS
Product CodeMKT 
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address Abbott Molecular, Inc. 1300 E Touhy Ave des Plaines, IL 60018

Supplemental Filings

A PHP Error was encountered

Severity: Notice

Message: Undefined offset: 0

Filename: fda.report/pma_item.php

Line Number: 132

Backtrace:

File: /var/www/fda.report/pma_item.php
Line: 132
Function: _error_handler

Supplement NumberDateSupplement Type
P200013Original Filing

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.